US2014234261A1PendingUtilityA1

Parvovirus Cancer Therapy and Combination with Chemotherapy

43
Assignee: OEFFENTLICHEN RECHTS DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DESPriority: Dec 28, 2007Filed: Mar 7, 2013Published: Aug 21, 2014
Est. expiryDec 28, 2027(~1.4 yrs left)· nominal 20-yr term from priority
Inventors:Jean RommelaereZahari RaykovJoerg SchlehoferIrina KiprijanovaTanja HeimbergerAssia AngelovaKarsten GeletnekyMarc Aprahamian
A61P 43/00A61P 35/00A61P 25/00A61P 1/18A61K 31/495C12N 2750/14032A61K 35/768A61K 31/7068A61K 31/4188
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.

Claims

exact text as granted — not AI-modified
1 . Pharmaceutical composition containing a parvovirus and a chemotherapeutic agent. 
     
     
         2 . The pharmaceutical composition of  claim 1  containing (a) a parvovirus and (b) a chemotherapeutic agent as separate entities. 
     
     
         3 .- 17 . (canceled)

Join the waitlist — get patent alerts

Track US2014234261A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.